Clinical Trials Browser

INDUSTRY × talazoparib × Genitourinary × Clear all

NCT04821622 2026-03-11

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT05650476 2025-06-12

Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076)

Neoplasm Metastasis, Prostatic Neoplasms

NCT04672460 2024-09-25

A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors

Phase 1 Completed

73 enrolled 18 charts

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT03148795 2024-04-05

A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer

Phase 2 Completed

128 enrolled 25 charts

Prostatic Neoplasms

NCT03875313 2022-02-17

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

Phase 1/2 Terminated

33 enrolled 14 charts

BreastGastrointestinalGenitourinary

Carcinoma, Renal Cell, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT01286987 2019-01-10

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

Phase 1 Completed

113 enrolled 39 charts

BreastClassical hematologyGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Fanconi Anemia, Complementation Group D1, Carcinoma, Ovarian Epithelial, Breast Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Ewing, Small Cell Lung Carcinoma